Archive | BIOgraph

Notes from BIO 2015 #1 Recap and Biotechnology Trends-M&A, Precision Medicine

Updated 6/25 Precision Medicine -Novel Prevention and Treatment Strategies Lead The Way A New Initiative on Precision Medicine — NEJM Over 15,000 attended BIO 2015 in Philadelphia including 1100 companies and more than 30 nations. The Exhibits and Partnering meetings were excellent opportunities for networking and dealmaking as usual. We attended several of the sessions and […]

Continue Reading 0

Biotech Trading Notes: AEGR, ARRY, CLVS, REGN, RPRX- Update 1 Market Rallies Post FED

No Taper Rallies Stocks and Bonds-Equities up almost 1% Most sectors and stocks turned bright green after FED announces “No Taper”. Biotech stocks are up with IBB up 1%. Drug stocks very strong due to dividend plays and lower 10 year yield (2.724%). Gold up $34 with weak dollar. Oil up 2.63% on energy stocks […]

Continue Reading 0

Kythera (KYTH) Soars on Phase III Fat Drug Update 1

Chin-Up and Out! KYTH traded 2.58M shares today closing near its gap up 25% this morning at $41.95 . There was distribution of stock probably from early investors to funds and retail. The market cap is $774M. As of June 30,2013 reporting the Company had Shareholder equity of $45.8M and Cash of about $76M. Insiders […]

Continue Reading 0

Biotech Bull Market Intact But Speculation Is In Check Update 1

Life Science Stocks in Corrective Mode-Look for Support Today   Update-winners could not hold tops with IBB ending day at $167, NASDAQ at 3321 The sector sell-off which began off the May top (up 30%) and picked up downward momentum in June is continuing today. However some large cap quality stocks in the Rayno Portfolio […]

Continue Reading 0

FED No Change: Market Down 1% as Less Monetary Accommodation Likely in Future

Downside Risk to Economy Diminished So Less “Extreme Monetary Policy” In the Future? Market Stable with downward bias :S&P flat to down 18 pts-10 Year Bond Yield At 2.28% up 3.9% FED Is Optimistic  about the economy: housing, consumer sentiment, financial backdrop but with fiscal drag. Bond purchases are tied to the economy. The FED […]

Continue Reading 0

Biotech Bull Market Momentum is Easing So Watch High Flyers: AEGR,CLVS etc- Update 6/16

Biotech Sell-Off Continues Nothing dramatic but the overall weakness in biopharmaceutical stocks is continuing today despite a strong performance by NASDAQ up 1.2% at 3464. With biotech having one of it best years of all time, profit taking is expected. The most popular ETFs IBB down 0.4% and XBI down 0.4% are weak but are […]

Continue Reading 0

Rayno Diagnostics and Tools Update: MYGN, SQNM Update 2 June 14

6/14  Supreme Court Ruling on Genetic Tests Takes Down Myriad Stock (MYGN $30.50)-Off Another 3% but still up 13% YTD. The Supreme Court ruling opens up competition for Myriad’s breast cancer tests as well as other genetic disease markers.The immediate reaction to the stock was initially positive yesterday but abruptly turned negative after stock downgrades […]

Continue Reading 0

Choppy Market with Macro in Forefront: Currency, Turkey, iRates

Life Science Stocks Holding Up Amidst Volatility-Stay Cautious Biotech stocks are mixed today as volatility from currency moves and violence in Turkey and the Middle East gives pause to investors. Bonds have corrected almost 5% prompting an exit from bond funds as the 10 Year Treasury hits the 2.19 % (high as 2.30) level up […]

Continue Reading 0

ASCO Day 3: News and Daily Movers in Risk-Off Mode CELG,GILD,IBB,PCYC

Market Correction Is Here-IBB at 170 off 2%+ The biotech sector sell-off (IBB at $170) continues today despite an effort to rally in the opening (IBB at $178). The biotech sector now tracks  the overall market and is no longer immune to macro issues and economic events. Market concerns this week are the volatility and […]

Continue Reading 0